Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E K Rowinsky

Showing results (111-120 of 159) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limitingE K Rowinsky, V Chaudhry, A A Forastiere, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 1997
Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removalA A Adjei, I I Budihardjo, E K Rowinsky, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2005
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancerM M Mita, L Ochoa, E K Rowinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 1996
A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemiaE K Rowinsky, S H Kaufmann, S D Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedulesE K Rowinsky, D A Noe, L B Grochow, et al.
Cancer Research|April 15, 1993
Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humansE K Rowinsky, D A Noe, D S Ettinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 1998
A phase I and pharmacologic study of DMP 840 administered by 24-hour infusionS O'Reilly, S D Baker, S Sartorius, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 1999
A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignanciesM A Villalona-Calero, T Petit, J Kuhn, et al.
The Journal of Clinical Investigation|April 1, 1995
Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the ratS J Sollott, L Cheng, R R Pauly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 1999
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancerS D Baker, M Wirth, P Statkevich, et al.
Pageof 16

Showing results (111-120 of 159) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limitingE K Rowinsky, V Chaudhry, A A Forastiere, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 1997
Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removalA A Adjei, I I Budihardjo, E K Rowinsky, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 3, 2005
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancerM M Mita, L Ochoa, E K Rowinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 1996
A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemiaE K Rowinsky, S H Kaufmann, S D Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedulesE K Rowinsky, D A Noe, L B Grochow, et al.
Cancer Research|April 15, 1993
Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humansE K Rowinsky, D A Noe, D S Ettinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 1998
A phase I and pharmacologic study of DMP 840 administered by 24-hour infusionS O'Reilly, S D Baker, S Sartorius, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 1999
A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignanciesM A Villalona-Calero, T Petit, J Kuhn, et al.
The Journal of Clinical Investigation|April 1, 1995
Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the ratS J Sollott, L Cheng, R R Pauly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 1999
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancerS D Baker, M Wirth, P Statkevich, et al.
Pageof 16